TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26372077

Group type: EXPERIMENTAL
Intervention: drawMD APP-aided pre-operative anesthesia education
Number of subjects: 0

Group type: COMPARATOR
Intervention: standard verbal education
Number of subjects: 0
Study: 25886108

Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg with dexamethasone 8 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg with dexamethasone 8 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Dexamethasone 8 mg alone (Control Group)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All groups (Granisetron, Ondansetron, Dexamethasone)
Number of subjects: 75
Study: 22399760

Group type: EXPERIMENTAL
Intervention: Visually induced gamma-band synchronization in monozygotic twins
Number of subjects: 80

Group type: COMPARATOR
Intervention: Visually induced gamma-band synchronization in dizygotic twins
Number of subjects: 80

Group type: COMPARATOR
Intervention: Visually induced gamma-band synchronization in unrelated subjects
Number of subjects: 80
Study: 19969615

Group type: EXPERIMENTAL
Intervention: Mozart music
Number of subjects: 20

Group type: COMPARATOR
Intervention: No music
Number of subjects: 20
Study: 18506738

Group type: EXPERIMENTAL
Intervention: 90 mg ambroxol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Internal standard: enalaprilat
Number of subjects: 24

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 24
Study: 15937908

Group type: EXPERIMENTAL
Intervention: Fulvestrant (250 mg monthly)
Number of subjects: 851

Group type: COMPARATOR
Intervention: Anastrozole (1 mg daily)
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 851
Study: 12473476

Group type: EXPERIMENTAL
Intervention: Sterillium Gel (85% ethanol-based) applied under occlusive patch during induction phase (nine applications over three weeks) and one application during challenge phase.
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sterillium Gel applied twice a day to the forearm for 14 days.
Number of subjects: 53
Study: 9838800

Group type: EXPERIMENTAL
Intervention: Protein supplementation (20 g/day, 5 days/week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7814240

Group type: EXPERIMENTAL
Intervention: Low-fat spread (40% fat wt/wt) containing 8 g of fish oil per 100 g of product (Group B)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: High-fat spread (80% fat wt/wt) containing 8 g of fish oil per 100 g of product (Group C)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Normal spreadable fat (Control Group A)
Number of subjects: 33
Study: 2547411

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0
Study: 322782

Group type: EXPERIMENTAL
Intervention: Haloperidol (3 mg daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 26
Study: 30503589

Group type: EXPERIMENTAL
Intervention: High-intensity functional exercise program
Number of subjects: 186

Group type: COMPARATOR
Intervention: Seated attention control activity
Number of subjects: 186
Study: 29737733

Group type: EXPERIMENTAL
Intervention: Voice training (6 hours of intensive vocal therapy one week before surgery)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Surgical operation only (control group)
Number of subjects: 26
Study: 27063895

Group type: EXPERIMENTAL
Intervention: Child-oriented play group
Number of subjects: 186

Group type: COMPARATOR
Intervention: Play-as-usual group
Number of subjects: 186
Study: 24256453

Group type: EXPERIMENTAL
Intervention: Group music therapy (GMT)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 99
Study: 22642415

Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB) with 1% lidocaine and 0.5% bupivacaine without epinephrine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Injectable saline placebo
Number of subjects: 30
Study: 19022441

Group type: EXPERIMENTAL
Intervention: Parietal peritoneal closure
Number of subjects: 340

Group type: COMPARATOR
Intervention: No parietal peritoneal closure (control)
Number of subjects: 340
Study: 17845590

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5 microg b.i.d. plus additional doses as needed (SMART)
Number of subjects: 3335

Group type: COMPARATOR
Intervention: Budesonide/formoterol 320/9 microg b.i.d. plus as-needed terbutaline
Number of subjects: 3335

Group type: COMPARATOR
Intervention: Salmeterol/fluticasone 50/250 microg b.i.d. plus as-needed terbutaline
Number of subjects: 3335
Study: 15112887

Group type: EXPERIMENTAL
Intervention: Vitamin E-modified dialyzers (CLE)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cellulosic dialyzers (CLS)
Number of subjects: 32
Study: 11948065

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9424683

Group type: EXPERIMENTAL
Intervention: Fentanyl (Group F) - 300 micrograms‐1200 micrograms/24 h in epidural perfusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methadone (Group M) - 9 mg‐18 mg/24 h in epidural perfusion
Number of subjects: 40
Study: 7946161

Group type: EXPERIMENTAL
Intervention: doxazosin, 4 mg daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 3429068

Group type: EXPERIMENTAL
Intervention: Sulbenicillin (2 g i.m. every 12 h for 7 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Piperacillin (2 g i.m. every 12 h for 7 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sulbenicillin
Number of subjects: 24
Study: 29164824

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Treatment (CRT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Treatment (CRT) plus Motivational Interviewing (MI)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (CRT only)
Number of subjects: 12
Study: 29037157

Group type: EXPERIMENTAL
Intervention: TEA with ropivacaine (Ep-R)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TEA with ropivacaine and morphine (Ep-RM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: IV morphine (IV-M)
Number of subjects: 30
Study: 25653155

Group type: EXPERIMENTAL
Intervention: Heat‐killed Lactobacillus gasseri TMC0356 (1.0×10(9) cfu/day for 4 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 23165172

Group type: EXPERIMENTAL
Intervention: Physiotherapy plus botulinum toxin injection (BTX)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 36
Study: 21118844

Group type: COMPARATOR
Intervention: Remifentanil 0 µg kg⁻¹ min⁻¹
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.5 µg kg⁻¹ min⁻¹
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Remifentanil 1.0 µg kg⁻¹ min⁻¹
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Remifentanil administration
Number of subjects: 38
Study: 19000302

Group type: EXPERIMENTAL
Intervention: Early extubation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Delayed extubation
Number of subjects: 16
Study: 16539549

Group type: EXPERIMENTAL
Intervention: Preemptive valdecoxib 40 mg at least 30 minutes before initial archwire placement
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Postoperative valdecoxib 40 mg two hours after initial archwire placement
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 12907532

Group type: EXPERIMENTAL
Intervention: Warmed nasal PD solutions (37 degrees C)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Room temperature nasal PD solutions (22 degrees C)
Number of subjects: 32
Study: 10638382

Group type: EXPERIMENTAL
Intervention: 200 mg of 4-androstene-3,17-dione (delta 4)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 200 mg of 4-androstene-3 beta,17 beta‐diol (delta 4 Diol)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8
Study: 8761562

Group type: EXPERIMENTAL
Intervention: Daily surveillance for illness and fortnightly malaria surveys in Group 1 schoolchildren.
Number of subjects: 249

Group type: COMPARATOR
Intervention: Two-monthly surveys and weekly home visits in Group 2 subjects.
Number of subjects: 249
Study: 8167771

Group type: EXPERIMENTAL
Intervention: 45 degrees position
Number of subjects: 19

Group type: COMPARATOR
Intervention: 90 degrees position
Number of subjects: 19
Study: 3213310

Group type: EXPERIMENTAL
Intervention: 5 mg fenoterol orally before PGE2-gel application
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo tablet before PGE2-gel application
Number of subjects: 23
Study: 30222842

Group type: EXPERIMENTAL
Intervention: Combat Application Tourniquet (C‐A‐T)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tactical Mechanical Tourniquet (TMT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison of C‐A‐T and TMT
Number of subjects: 24
Study: 28116968

Group type: EXPERIMENTAL
Intervention: Continuous interscalene block (CISB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Subacromial infusion of local anesthetic (CSIA)
Number of subjects: 40
Study: 24714184

Group type: EXPERIMENTAL
Intervention: Tailored education program using a touch‐screen computer
Number of subjects: 47

Group type: COMPARATOR
Intervention: Non-tailored education (booklet on asthma)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Tailored education program
Number of subjects: 47
Study: 22525770

Group type: EXPERIMENTAL
Intervention: Moderate-intensity treadmill walking
Number of subjects: 36

Group type: COMPARATOR
Intervention: Seated rest
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: N-back task
Number of subjects: 36
Study: 19889524

Group type: COMPARATOR
Intervention: Standard healthy diet
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diet + PS (2 g/day)
Number of subjects: 40
Study: 17337065

Group type: EXPERIMENTAL
Intervention: I125 brachytherapy
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 532

Group type: COMPARATOR
Intervention: Radiation dose of 24 Gy or higher
Number of subjects: 532
Study: 16261947

Group type: EXPERIMENTAL
Intervention: oxymetazoline hydrochloride
Number of subjects: 247
Study: 11854116

Group type: EXPERIMENTAL
Intervention: rFGF2 at 0, 0.3, 3, or 30 microg/kg
Number of subjects: 337

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: rFGF2 at 30 microg/kg
Number of subjects: 337
Study: 9666577

Group type: EXPERIMENTAL
Intervention: Cefoperazone sodium for 24 hr.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cefotaxime sodium for 120 hr.
Number of subjects: 50
Study: 7992138

Group type: EXPERIMENTAL
Intervention: Dramatic video 'Shadows of the Heart'
Number of subjects: 106
Study: 2568210

Group type: EXPERIMENTAL
Intervention: MK-912 2 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: MK-912 0.2 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31374015

Group type: EXPERIMENTAL
Intervention: Xinnaoning capsule (3 pills, 3 times daily for 12 weeks)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo (3 pills, 3 times daily for 12 weeks)
Number of subjects: 240
Study: 28874142

Group type: EXPERIMENTAL
Intervention: cART with 800 mg efavirenz
Number of subjects: 61
Study: 25138109

Group type: EXPERIMENTAL
Intervention: HIIT (4 × 4 min at 90% of HRmax)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 20

Group type: COMPARATOR
Intervention: CON (control condition)
Number of subjects: 20
Study: 23273831

Group type: EXPERIMENTAL
Intervention: Workshop training in evidence-based motivational interviewing (MI) interventions and organizational development activities at intervention sites.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Care as usual at control sites.
Number of subjects: 20
Study: 21649516

Group type: EXPERIMENTAL
Intervention: Verum moxibustion at around 44°C
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham moxibustion device at 39°C
Number of subjects: 30
Study: 18637084

Group type: EXPERIMENTAL
Intervention: LAMP (Locate, Align, Mark, Puncture)
Number of subjects: 101

Group type: COMPARATOR
Intervention: LAP (Locate, Align, Puncture)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both LAMP and LAP
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Most experienced operators
Number of subjects: 101
Study: 16436149

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 198

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 198
Study: 12958722

Group type: EXPERIMENTAL
Intervention: Lansoprazole plus Cisapride and Sucralfate
Number of subjects: 248

Group type: COMPARATOR
Intervention: Ranitidine plus Cisapride and Sucralfate
Number of subjects: 248
Study: 10875050

Group type: EXPERIMENTAL
Intervention: Paroxetine (20‐50 mg/day)
Number of subjects: 861

Group type: EXPERIMENTAL
Intervention: Paroxetine (20, 40, or 60 mg/day)
Number of subjects: 861

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 861
Study: 9172207

Group type: EXPERIMENTAL
Intervention: pain-incompatible imagery
Number of subjects: 39

Group type: COMPARATOR
Intervention: control
Number of subjects: 39
Study: 1399203

Group type: EXPERIMENTAL
Intervention: 125 mg terbinafine twice daily
Number of subjects: 39

Group type: COMPARATOR
Intervention: 250 mg terbinafine once daily
Number of subjects: 39
Study: 3890768

Group type: EXPERIMENTAL
Intervention: Antilipopolysaccharide gammaglobulin given intramuscularly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30742915

Group type: EXPERIMENTAL
Intervention: Combination controller therapy
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Specialty care
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Allergen sensitization
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Poverty status
Number of subjects: 222
Study: 30562322

Group type: EXPERIMENTAL
Intervention: Swimming training (SWM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 100
Study: 26419197

Group type: EXPERIMENTAL
Intervention: Breast milk intake
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Energy intake from breast milk
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Protein intake from breast milk
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Fatty-acid composition
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Nutrient composition of breast milk
Number of subjects: 174
Study: 23972329

Group type: EXPERIMENTAL
Intervention: ParkFit program
Number of subjects: 586
Study: 22154417

Group type: EXPERIMENTAL
Intervention: Magnetically guided capsule endoscope (MGCE)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Gastroscopy (control)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Overall diagnostic yield for both MGCE and gastroscopy
Number of subjects: 61
Study: 20451788

Group type: EXPERIMENTAL
Intervention: Contamination with saliva before TSEP application (153 teeth)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Contamination with saliva after TSEP application (115 teeth)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Uncontaminated control group (263 teeth)
Number of subjects: 46
Study: 18617486

Group type: EXPERIMENTAL
Intervention: Oral co‐trimoxazole
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Oral co‐trimoxazole (per protocol analysis)
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Placebo (per protocol analysis)
Number of subjects: 1003
Study: 27945464

Group type: EXPERIMENTAL
Intervention: Cevimeline 30 mg TID (escalated to 45 mg TID if no improvement)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570
Study: 11815395

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg daily for 2 months)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Antioxidant mixture (containing vitamin C, alpha-lipoic acid, and vitamin E)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 10355512

Group type: EXPERIMENTAL
Intervention: Lansoprazole (LNS) 30 mg b.i.d. + clarithromycin (CLR) 250 mg b.i.d. + metronidazole (MTR) 250 mg q.i.d.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lansoprazole (LNS) 30 mg b.i.d. + amoxycillin (AMOX) 1 g b.i.d. + MTR 250 mg q.i.d.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lansoprazole (LNS) 30 mg b.i.d. + CLR 250 mg b.i.d. + AMOX 1 g b.i.d.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 150
Study: 8952741

Group type: EXPERIMENTAL
Intervention: Cibenzoline (260 mg/day, reduced to 130 mg/day for elderly patients)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Propafenone (600 mg/day, reduced to 300 mg/day for elderly patients)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cibenzoline
Number of subjects: 65

Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 65
Study: 1682159

Group type: EXPERIMENTAL
Intervention: 120mg terfenadine twice daily for 4 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6756798

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment (halcinonide ointment, 0.1 percent)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo (ointment base)
Number of subjects: 214
Study: 31955478

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided continuous deep serratus anterior plane block (SAPB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Surgically placed continuous thoracic paravertebral block (SPVB)
Number of subjects: 40
Study: 30805213

Group type: EXPERIMENTAL
Intervention: High-volume exercise group (300 min/week)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Moderate-volume exercise group (150 min/week)
Number of subjects: 334
Study: 28352069

Group type: EXPERIMENTAL
Intervention: N-Butylphthalide and hyperbaric oxygen therapy (HBO)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (HBO only)
Number of subjects: 184
Study: 25920944

Group type: EXPERIMENTAL
Intervention: Professionally designed consent pack
Number of subjects: 1950

Group type: EXPERIMENTAL
Intervention: Phone reminders
Number of subjects: 1950

Group type: COMPARATOR
Intervention: Prior-notification postcard
Number of subjects: 1950

Group type: COMPARATOR
Intervention: Standard consent pack
Number of subjects: 1950

Group type: COMPARATOR
Intervention: Postal reminders
Number of subjects: 1950
Study: 24408785

Group type: EXPERIMENTAL
Intervention: Clinically indicated replacement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine replacement
Number of subjects: 0
Study: 21819615

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Statin therapy (patients >58 years of age)
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Statin therapy (APACHE II score >22)
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Statin therapy (diabetic patients)
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Statin therapy (patients on vasopressor therapy)
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Statin therapy (admitted with severe sepsis)
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Statin therapy (creatinine ≤ 100 μmol/L)
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Statin therapy (GCS ≤ 9)
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Statin therapy (simvastatin, equipotent doses ≥ 40 mg)
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 763
Study: 20048489

Group type: EXPERIMENTAL
Intervention: Periarticular injection with hyaluronic acid (HA) + standard of care (RICE)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo injection (PL) + standard of care (RICE)
Number of subjects: 158
Study: 17334536

Group type: EXPERIMENTAL
Intervention: Lansoprazole (60 mg for 5 days)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Lansoprazole treatment in H. pylori-positive group
Number of subjects: 23
Study: 15572316

Group type: EXPERIMENTAL
Intervention: High-tension (90 N)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Low-tension (45 N)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups (High-tension and Low-tension)
Number of subjects: 49
Study: 11280168

Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 g/kg body wt)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (cola)
Number of subjects: 26
Study: 9426843

Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) 3,200 mg/day for 3 months
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) + hyperimmune CMV immunoglobulins (CMV Igs)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Acyclovir (ACV)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Acyclovir (ACV) with or without CMV Ig
Number of subjects: 28
Study: 8097813

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 1536
Study: 2949910

Group type: EXPERIMENTAL
Intervention: Human alpha-ANP (1-28) infusion at 1.2 pmol min-1 kg-1 for 3 hours
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Human alpha-ANP (1-28) infusion
Number of subjects: 7

Group type: COMPARATOR
Intervention: Vehicle infusion (control)
Number of subjects: 7
Study: 30629020

Group type: EXPERIMENTAL
Intervention: Enhanced recovery (nonopioid analgesia, patient-directed oral intake, early ambulation)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard treatment (opioid analgesia, physician-directed diet)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Enhanced recovery
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 46
Study: 30503129

Group type: EXPERIMENTAL
Intervention: Growth hormone co-treatment during IVF
Number of subjects: 62

Group type: COMPARATOR
Intervention: Non-GH-treated patients of the same age and ovarian reserve
Number of subjects: 62
Study: 26904985

Group type: EXPERIMENTAL
Intervention: Randomized response techniques (RRTs)
Number of subjects: 659
Study: 24668315

Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101